If the plasma level is in the high-risk region of the nomogram, the risk of developing hepatotoxicity is 60% or higher, and antidote therapy is warranted
Real-world data confirms sustained weight loss, improved cardiovascular markers, and reduced diabetes incidence in GLP-1 users
There is no single 'right' dosetreatment is personalized to your body's response and your weight loss goals
This medication mimics GLP-1, which normally acts to slow the movement of food out of your stomach and makes you feel fuller longer
Studies have shown that at doses high enough to fully saturate intestinal B12 receptors, oral B12 is effective, despite a lack of intrinsic factor
The rise of Ozempic face: analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists